Assuntos
Melanoma/complicações , Síndromes Paraneoplásicas Oculares/patologia , Neoplasias Cutâneas/complicações , Idoso de 80 Anos ou mais , Humanos , Metástase Linfática , Masculino , Melanoma/diagnóstico por imagem , Melanoma/patologia , Síndromes Paraneoplásicas Oculares/diagnóstico por imagem , Radiografia Torácica , Neoplasias Cutâneas/diagnóstico por imagem , Neoplasias Cutâneas/patologia , Tomografia de Coerência ÓpticaRESUMO
Psychiatrists working in hospital and in private practice took part in co-operative trial aimed at evaluating the effectiveness and safety of bromazepam. The study was of the open type and involved 10 hospital patients and 20 ambulatory patients. The same protocole was followed for each patient. Twenty-five patients (including 5 in hospital) had anxiety neurosis; the remaining 5 had anxiety following weaning from alcohol. The anxiolytic effects of the drug, determined by means of Hamilton's anxiety scale and overall clinical judgement, were generally found to be satisfactory. The effective doses ranged from 1 to 3 tablets per day in ambulatory patients and from 3 to 5 tablets per day in hospital patients. The main side-effects were related to unwanted sedation; they only occurred with the higher doses and rarely interfered with the beneficial effects of bromazepam.